Pemetrexed in Treating Patients with Metastatic Bladder Cancer |
Li, Qing
(Department of Urology, The Fourth Affiliated Hospital of Harbin Medical University)
Li, Jian-Zhang (Department of Urology, The Fourth Affiliated Hospital of Harbin Medical University) Xu, Wan-Hai (Department of Urology, The Fourth Affiliated Hospital of Harbin Medical University) Gao, Lin (Department of Urology, The Fourth Affiliated Hospital of Harbin Medical University) |
1 | Babjuk M. et al (2011). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol, 59, 997-1008. DOI |
2 | Bamias A, Aravantinos G, Deliveliotis C, et al (2004). Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol, 22, 220-8. |
3 | Dreicer R, Li H, Cooney MM, et al (2008). Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer, 112, 2671-5. DOI |
4 | Galsky MD, Mironov S, Iasonos A, et al (2007). Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs, 25, 265-70. DOI |
5 | Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7. |
6 | Liu J, Huang XE, Feng JF (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90. DOI |
7 | Lu YY, Huang XE, Cao J (2013). Phase II study on Javanica oil emulsion injection (Yadanzi) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 4791-4. DOI ScienceOn |
8 | McCaffrey JA, Hilton S, Mazumdar M, et al (1997). Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol, 15, 1853-57. |
9 | Margulis V. et al (2009). Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 115, 1224-33. DOI |
10 | Munoz JJ, Ellison LM (2000). Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol, 164, 1523-5. DOI |
11 | Ploeg M, Aben KK, Kiemeney LA (2009). The present and future burden of urinary bladder cancer in the world. World J Urol, 27, 289-93. DOI |
12 | Roth BJ, Dreicer R, Einhorn LH, et al (1994). Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 12, 2264-70. |
13 | Sweeney C, Roth B, Kabbinavar F, et al (2006). Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol, 24, 3451-7. DOI |
14 | Tian GY, Miu M, Huang XE (2014). Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev, 15, 8475-8. DOI |
15 | von der Maase H, Hansen S, et al (2000). Gemcitabine and cisplatin versus methotrextate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 18, 3068-77. |
16 | Wei GL, Huang XE, Huo JG, et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6. DOI ScienceOn |
17 | Wu XY, Huang XE, Cao J, et al (2014). A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Asian Pac J Cancer Prev, 15, 5941-4. DOI |